The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Agendia; Amgen; AstraZeneca; Celgene; Clovis Oncology; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics (Inst); Lilly; MSD Oncology; Myriad Genetics; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche/Genentech; Seagen; Tesaro
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); CureVac; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics (Inst); Pfizer; Roche (Inst); Tesaro; Vaccibody (Inst)
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Tesaro (Inst); Vaccibody (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).
 
Philipp Harter
Honoraria - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Lilly; MSD Oncology; Roche; Sotio; Stryker; Zai Lab
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Immunogen; Merck; Roche; Tesaro
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Roche (Inst)
 
Frederik Marmé
No Relationships to Disclose
 
Patricia Pautier
Consulting or Advisory Role - AstraZeneca (Inst); MSD Oncology (Inst); MSD vaccin (Inst); Onxeo (Inst); PharmaMar (Inst)
Research Funding - Onxeo (Inst); PharmaMar (Inst)
Expert Testimony - Clovis Oncology (Inst); Onxeo (Inst); Roche
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; MSD Oncology; OSE Immunotherapeutics; Roche
 
Alexander Reuss
No Relationships to Disclose
 
Kristina Lindemann
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; MSD
Research Funding - GlaxoSmithKline (Inst)
 
Christian Kurzeder
Honoraria - AstraZeneca (Inst); AstraZeneca (Inst); GlaxoSmithKline (Inst); Lilly (Inst); PharmaMar (Inst); Roche (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Genomic Health (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst)
Expert Testimony - AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Els Van Nieuwenhuysen
No Relationships to Disclose
 
Clemens Schmitt
Honoraria - Janssen; Roche
Consulting or Advisory Role - Janssen; Roche
Speakers' Bureau - Janssen; Roche
Travel, Accommodations, Expenses - Janssen; Roche
 
Nadin Cron
No Relationships to Disclose
 
Andres Redondo
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; PharmaMar
Research Funding - Eisai (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar